Harmony Biosciences Azioni (NASDAQ: HRMY)

Ultime notizie per Harmony Biosciences (NASDAQ:HRMY) Azioni

Harmony Biosciences

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Holdings Inc

Former President Donald Trump has reiterated his commitment to imposing tariffs on cars imported from China and Mexico, aiming to protect American automotive jobs.
What Happened: During an interview with Patrick Bet-David released on Thursday, Trump emphasized the critical role these tariffs would play in safeguarding the U.S. auto industry.
&#8220;I hope the union workers, auto workers understand that I saved their jobs,&#8221; he said.
Trump highlighted a massive car manufacturing plant in Mexico, which he described as potentially one of the largest in the world. He expressed concerns that vehicles from this plant could inundate the U.S. market, leaving little room for American-made cars.
&#8220;That would mean that our car industry is wiped out,&#8221; Trump said.
See Also: <a href="https://www.benzinga.com/news/24/10/41328039/as-elon-musk-unveils-cybercab-uber-ceo-weighs-in-on-robotaxi-competiton-from-waymo-tesla-dont-think?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">As Elon Musk Unveils Cybercab, Uber CEO Weighs In On Robotaxi Competiton From Waymo, Tesla: &#8216;Don&#8217;t Think This Is Going To Be A Winner-Take-All Marketplace&#8217;</a>
Why It Matters: In September, Trump <a href="https://www.benzinga.com/news/24/09/40913456/trump-vows-200-tariffs-on-chinese-made-cars-in-mexico-warns-of-us-auto-industry-collapse-if-kamala-h">proposed a 200% tariff</a> on vehicles produced by alleged Chinese factories in Mexico, as reported in a town hall event in Flint, Michigan. He warned that if Vice President Kamala Harris were elected, the U.S. auto industry could collapse within two to three years due to electric vehicle production shifting to China.
Additionally, during a <a href="https://www.benzinga.com/general/politics/24/10/41279272/donald-trump-pushes-tariffs-on-chinese-cars-in-detroit-visit-vows-to-revamp-industry">visit to the Detroit Economic Club</a> in October, Trump reiterated his commitment to tariffs on Chinese cars, vowing to revamp the industry. He also commented on economic indicators, although some of his statements on inflation and interest rates were inaccurate.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41369986/lucid-stock-is-tumbling-wednesday-whats-driving-the-action?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Lucid Stock Is Tumbling Wednesday: What&#8217;s Driving The Action?</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Wikimedia Commons

News

General

Trump Defends His Plans To Impose 200% Tariffs On Cars Imported From China, Mexico: 'Hope Union Workers Understand That I Saved Their Jobs'

Amid ongoing global economic recovery efforts, Kristalina Georgieva, Managing Director of the International Monetary Fund, has issued a cautionary note regarding persistent challenges such as high debt and low growth. Her remarks come as the U.S. and EU implement rate cuts to tackle inflation.
What Happened: Georgieva highlighted that despite progress, governments are increasingly reliant on borrowing, which, coupled with &#8220;anemic growth,&#8221; complicates debt management. She praised central banks for their inflation control efforts but noted uneven benefits across regions, with some still facing high prices and related unrest, CNBC <a href="https://www.cnbc.com/2024/10/17/imf-chief-warns-low-growth-and-high-debt-weigh-on-global-economy.html">reported</a> on Friday.
"It's not yet time to celebrate," she said.
"When we look into the challenges ahead of us, the biggest one is low growth, high debt. This is where we can and must do better.&#8221;
Georgieva&#8217;s comments precede the 2024 annual meetings of the IMF and World Bank Group in Washington, D.C., where global economic issues will be discussed. She also pointed out that international trade is no longer the &#8220;engine of growth&#8221; it once was, citing restrictive policies and <a href="https://www.benzinga.com/news/24/09/40914629/china-warns-eu-tariffs-on-evs-will-harm-trade-with-germany">U.S.-EU tariffs against China</a> as potential risks. Additionally, she expressed concern over geopolitical tensions, particularly in the Middle East, affecting global financial stability.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41331839/financial-sector-hits-record-highs-as-goldman-sachs-bank-of-america-citi-beat-q3-ea?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Financial Sector Hits Record Highs As Goldman Sachs, Bank of America, Citi Beat Q3 Earnings Expectations</a>
Why It Matters: Georgieva&#8217;s comment arrived a day after the European Central Bank (ECB) <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41382372/ecb-slashes-rates-again-will-jerome-powell-take-this-as-cue-for-another-fed-rate-"> cut interest rates</a> for the third time this year to stimulate a sluggish economy, shifting focus from inflation control to economic growth. This move follows the Federal Reserve&#8217;s 50 basis point rate cut in September, marking a significant policy shift as both regions tackle economic challenges.
Meanwhile, the U.S. faces a staggering debt situation, with estimates suggesting a<a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40368118/true-us-debt-is-175-trillion-former-coinbase-cto-on-unpayable-crisis"> true national debt </a>of $175 trillion when accounting for entitlements like Social Security and Medicare. This escalating debt underscores the urgency of addressing fiscal challenges.
In China, the government is reportedly considering issuing $850 billion in<a href="https://www.benzinga.com/markets/asia/24/10/41324527/as-chinas-stimulus-hype-wanes-beijing-reportedly-weighs-850b-special-treasury-bonds-to-stimulate-eco"> special treasury bonds</a> to stimulate its slowing economy and manage local debt. These developments highlight the global nature of economic challenges and the varied approaches being taken to address them.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41372368/mark-cuban-battles-former-trump-advisor-for-suggesting-a-child-could-do-american-auto-workers-job-pa?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Battles Former Trump Advisor Over Ex-President&#8217;s Comments On American Auto Workers: &#8216;He Still &nbsp;Thinks It&#8217;s 1965&#8217; (UPDATED)</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Macro Economic Events

Global

Economics

As US Tackles Inflation With Rate Cuts, IMF MD Sounds Alarm: 'Not Yet Time To Celebrate' Amid Looming Low Growth, High Debt

The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) will release earnings results for its first quarter, before the <a href="https://www.benzinga.com/quote/PG/earnings">opening bell on Friday, Oct. 18.</a>
Analysts expect the Cincinnati, Ohio-based bank to report quarterly earnings at $1.90 per share, up from $1.83 per share in the year-ago period. Procter &amp; Gamble projects to report revenue of $21.91 billion for the recent quarter, compared to $19.78 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 30, Procter &amp; Gamble reported fourth-quarter FY24 sales of $20.53 billion (flat Y/Y), missing the analyst consensus estimate of $20.74 billion.
Procter &amp; Gamble shares fell 0.1% to close at $172.28 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TCOM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5890a92043eaaa0001d69b01/linda-bolton%20weiser">DA Davidson analyst Linda Bolton Weiser</a> maintained a Neutral rating with a price target of $159 on Oct. 15. This analyst has an accuracy rate of 61%.</li>
<li>Barclays analyst Lauren Lieberman downgraded the stock from Overweight to Equal-Weight with a price target of $163 on Sept. 30. This analyst has an accuracy rate of 63%.</li>
<li>JP Morgan analyst Andrea Teixeira maintained an Overweight rating and increased the price target from $179 to $186 on Sept. 19. This analyst has an accuracy rate of 61%.</li>
<li>TD Cowen analyst Robert Moskow initiated coverage on the stock with a Buy rating and a price target of $189 on July 23. This analyst has an accuracy rate of 65%.</li>
<li>Stifel analyst Mark Astrachan maintained a Hold rating and raised the price target from $157 to $161 on July 22. This analyst has an accuracy rate of 78%.</li>
</ul>
Considering buying PG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="482" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-1024x482.png" alt="" class="wp-image-602127" style="width:665px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-1024x482.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-300x141.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-768x362.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158.png 1365w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>

Earnings

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Procter & Gamble Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans,Benson &amp; Hedges Inc. (RBH), that the court-appointed mediator and monitor in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding filed a proposed plan of compromise and arrangement (Proposed Plan) outlining certain terms of a comprehensive resolution of tobacco product-related claims and litigation in Canada against RBH and its affiliates. The court-appointed mediator and monitors also filed substantially similar proposed plans for Imperial Tobacco Canada Limited and Imperial Tobacco Company Limited (together, ITL) and JTI-Macdonald Corp. (JTIM).
Under the Proposed Plan, if ultimately approved and implemented, RBH, ITL and JTIM (the Companies) would pay an aggregate settlement amount of CAD 32.5 billion (approximately USD 23.5 billion). This amount would be funded by an upfront payment equal to the Companies' cash and cash equivalents on hand in Canada plus certain court deposits (subject to an aggregate withholding of CAD 750 million (approximately USD 540 million) for working capital inclusive of cash pledged as collateral) and annual payments based on a percentage of the Companies' net income after taxes (excluding that generated by certain non-combustible products including heat-not-burn, e-vapor and nicotine pouch products) until the aggregate settlement amount is paid. As stated in the Proposed Plan, the issue of allocation of the CAD 32.5 billion aggregate settlement as between the Companies in the CCAA proceedings remains unresolved.
"After years of mediation, we welcome this important step towards the resolution of long-pending tobacco product-related litigation in Canada," said Jacek Olczak, Chief Executive Officer of PMI. "Although important issues with the plan remain to be resolved, we are hopeful that this legal process will soon conclude, allowing RBH and its stakeholders to focus on the future."

Legal

Philip Morris, Imperial Tobacco, JTI-Macdonald Face $23.5B Settlement in Canada Tobacco Lawsuits

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cloudflare.com%2F&amp;esheet=54138023&amp;newsitemid=20241018840279&amp;lan=en-US&amp;anchor=Cloudflare%2C+Inc.&amp;index=1&amp;md5=3e1a02702fd6e8744473a752dd19c5f5">Cloudflare, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), the leading connectivity cloud company, today announced the opening of a new headquarters and technical hub in Lisbon, Portugal to further support its growing EMEA operations and offices in London, Paris, Munich, and Dubai. Portugal already represents a growing Cloudflare team.
Today, Cloudflare's network currently spans 58 cities in Europe, including Lisbon, Portugal, which was announced in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fblog.cloudflare.com%2Famsterdam-to-zhuzhou-cloudflare-global-network%2F&amp;esheet=54138023&amp;newsitemid=20241018840279&amp;lan=en-US&amp;anchor=2016&amp;index=2&amp;md5=89c437ed99560575fd137ba7cd354fa5">2016</a>. Cloudflare announced its first office in Lisbon in 2019. Since establishing an office in the region, the company has grown from 14 employees to more than 350 in Portugal. Cloudflare plans to significantly increase its presence in Lisbon over the coming years.
Cloudflare celebrated the official opening of its new office with a ribbon cutting ceremony, followed by a reception attended by Portugal's Minister of Economy, Mr. Pedro Reis, along with other Portuguese officials. Top Cloudflare executives were also in attendance, including Cloudflare co-founder and CEO Matthew Prince, and John Graham-Cumming, CTO &amp; Head of the Lisbon office, which he opened in July 2019.

Government

Regulations

Cloudflare Expands European Operations With New Lisbon Headquarters, Plans Major Workforce Growth

Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) will release earnings results for its third quarter, before the<a href="https://www.benzinga.com/quote/SLB/earnings"> opening bell on Friday, Oct. 18.</a>
Analysts expect the Buffalo, New York-based company to report quarterly earnings at 88 cents per share, up from 71 cents per share in the year-ago period. SLB projects to report revenue of $9.25 billion for the quarter, compared to $7.58 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Thursday, SLB agreed to sell its interests in Palliser Block.
SLB shares gained 0.7% to close at $43.99 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/SLB/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/580874cb846faa000106ac9d/david-anderson">Barclays analyst David Anderson</a> maintained an Overweight rating and cut the price target from $67 to $63 on Oct. 16. This analyst has an accuracy rate of 63%.</li>
<li>Stifel analyst Stephen Gengaro maintained a Buy rating and cut the price target from $65 to $62 on Oct. 11. This analyst has an accuracy rate of 60%.</li>
<li>BMO Capital analyst Philip Jungwirth maintained an Outperform rating and cut the price target from $60 to $58 on Oct. 10. This analyst has an accuracy rate of 61%.</li>
<li>JP Morgan analyst Arun Jayaram maintained an Overweight and cut the price target from $64 to $60 on Oct. 1. This analyst has an accuracy rate of 65%.</li>
<li>Morgan Stanley analyst Connor Lynagh maintained an Overweight rating and slashed the price target from $65 to $60 on Sept. 16. This analyst has an accuracy rate of 60%.</li>
</ul>
Considering buying SLB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="511" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-1024x511.png" alt="" class="wp-image-602108" style="width:705px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-1024x511.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-768x383.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157.png 1338w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>

SLB Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Thursday.
U.S. stocks settled mostly higher on Thursday, with the Dow Jones index climbing to a new record close following the release of economic data.
U.S. initial jobless claims fell by 19,000 in the week ending Oct. 12. U.S. retail sales rose 0.4% month-over-month in September compared to a 0.1% increase in August and higher than market estimates of a 0.3% rise. The Philadelphia Fed Manufacturing Index climbed to 10.3 in October compared to 1.7 in September and topping market estimates of 3.
Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) shares jumped around 9.8% on Thursday following better-than-expected third-quarter earnings and strong fourth-quarter guidance
Most sectors on the S&amp;P 500 closed on a negative note, with utilities, communication services, and real estate stocks recording the biggest losses on Thursday. However, energy and information technology stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed higher by around 161 points to 43,239.05 on Thursday. The S&amp;P 500 slipped 0.02% to 5,841.47, while the Nasdaq Composite rose 0.04% at 18,373.61 during Thursday's session.
Investors are awaiting earnings results from American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>), The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), and Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 71.5, the index remained in the &#8220;Greed&#8221; zone on Thursday, versus a prior reading of 69.5.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>
Photo courtesy: Shutterstock

TSMC, Strong Economic Data Push Dow To Fresh Record High: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) to report quarterly earnings at $3.28 per share on revenue of $16.67 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. American Express shares gained 1.8% to $290.91 in after-hours trading.</li>
<li>Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported stronger-than-expected third-quarter financial results, posting revenue of $9.825 billion, up 15% year-over-year, versus market estimates of $9.769 billion. The company ended the third quarter with 282.72 million global paid subscribers, up 14.4% year-over-year. Netflix shares climbed 5.1% to $722.35 in the after-hours trading session.</li>
<li>Analysts are expecting The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) to post quarterly earnings at $1.90 per share on revenue of $21.91 billion. The company will release earnings before the markets open. Procter &amp; Gamble shares gained 0.1% to $172.50 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) posted better-than-expected third-quarter financial results. The company also said it obtained regulatory clearance in South Korea for the da Vinci 5 surgical system in October. Intuitive Surgical shares climbed 6.1% to $502.80 in the after-hours trading session.</li>
<li>Analysts expect Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) to report quarterly earnings at 88 cents per share on revenue of $9.25 billion before the opening bell. SLB shares rose 0.4% to $44.16 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>
Photo courtesy: Shutterstock

ISRG

NFLX

Netflix, American Express And 3 Stocks To Watch Heading Into Friday

MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) founder Michael Saylor encouraged those who doubt the upside potential of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to go short on the company's stock, assuring that it would never sell the cryptocurrency.
What happened: During an interview with journalist Madison Reidy that aired Thursday, Saylor asked skeptics to "love" MicroStrategy if they really "hate" Bitcoin.
"We&#8217;re the perfect instrument to short because I promise you, I won&#8217;t sell it. We&#8217;re going to be leveraged long on Bitcoin," said Saylor, one of the most passionate advocates of the cryptocurrency.
&#8220;I want you to love us if you really hate BTC.&#8221;
Saylor said as a company, MicroStrategy has been consistent and transparent in its policy of buying and holding on to Bitcoin, and it was up to market participants to decide if they wanted to buy, sell, or short their shares.
"When I was a younger man I would have been concerned about people shorting my stock but now I&#8217;m not," Saylor added.&nbsp;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41373332/donald-trump-backed-world-liberty-financial-off-to-a-slow-start-raises-just-4-of-the-token">Donald Trump-Backed World Liberty Financial Off To A Slow Start — Raises Just 4% Of The Token Fundraising Target</a>
Why It Matters: Saylor&#8217;s remarks came amid MicroStratgy&#8217;s audacious Bitcoin gambit, which has transformed the software development firm into a proxy for the world&#8217;s greatest digital asset.
MicroStrategy <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40306998/since-embracing-bitcoin-4-years-ago-michael-saylors-microstrategy-has-outperformed-warren-">adopted Bitcoin as its primary reserve asset</a> in 2020, becoming the first publicly listed company to pursue this strategy, and hasn't looked back since then. Today, it holds over $17 billion of its total capital in Bitcoin, <a href="https://bitcointreasuries.net/">according</a> to bitcointreasuries.net.
Saylor projects that by 2045, <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40916462/michael-saylor-bitcoin-to-hit-13m-by-2045-will-get-us-to-a-different-place#:~:text=Michael%20Saylor%3A%20Bitcoin%20To%20Hit,To%20A%20Different%20Place'%20%2D%20Benzinga">Bitcoin will constitute 7% of global financial capital</a>, implying a $13 million price per Bitcoin.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Michael Saylor: Why MicroStrategy's Bitcoin funding is NOT a glitch" width="500" height="281" src="https://www.youtube.com/embed/eThjo9wYoF0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Price Action: At the time of writing, Bitcoin was exchanging hands at $67,931.57, up 0.98% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Shares of MicroStrategy closed down 0.35% to $193.42 during Thursday's regular trading session.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41372654/peter-schiff-questions-trump-inspired-bitcoin-pump-one-of-the-promises-he-did-not-make-was">Peter Schiff Question &#8216;Trump-Inspired&#8217; Bitcoin Pump: &#8216;One Of The Promises He Did Not Make Was To Buy Any&#8217;</a></li>
</ul>
Photo courtesy: Wikimedia

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

MicroStrategy Boss Michael Saylor Taunts Bitcoin Doubters, Challenges Them To Short Company's Stock: 'I Want You To Love Us If You Really Hate BTC'

Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) subsidiary Waymo is providing riders who <a href="https://www.benzinga.com/news/24/06/39494723/waymo-autonomous-rides-now-available-to-everyone-in-san-francisco-heres-how-you-can-enjoy-driverless">avail an autonomous ride</a> to select transit stations in San Francisco and the Peninsula $3 credit in a bid to promote public transportation, the company said on Thursday.
What Happened: Waymo will credit $3 to riders&#8217; accounts if they take an autonomous ride to or from eligible Bay Area transit stations. These credits can be used for future rides.
The program started on Oct. 17 and will go on till Nov.15. The credits can be used until Dec. 31, according to a statement from Waymo. 
&#8220;By offering electric rides on demand and improving access to public transit, Waymo One is making daily travel more sustainable and convenient,&#8221; said Adam Lenz, Head of Sustainability and Environment at Waymo.
Why It Matters: Waymo currently operates a fleet of all-electric vehicles that have been customized to enable autonomous driving. The company is delivering over 100,000 paid autonomous rides every week to the public, the company said on Thursday.
Automotive research firm&nbsp;S&amp;P Global Mobility&nbsp;said in September that it deems&nbsp;<a href="https://www.benzinga.com/news/24/09/40792410/us-autonomous-vehicle-sales-to-hit-230k-by-2034-after-progress-resumes-at-alphabets-waymo-gms-cruise" target="_blank" rel="noreferrer noopener">Waymo to be the frontrunner&nbsp;</a>in the field of autonomous vehicles in the U.S.&nbsp;
&nbsp;In July, Alphabet committed&nbsp;to a new multiyear&nbsp;<a href="https://www.benzinga.com/news/24/07/39924838/alphabet-commits-to-another-5b-investment-in-waymo-tesla-ceo-elon-musk-takes-jibe-at-cash-burn-in-un" target="_blank" rel="noreferrer noopener">investment of $5 billion into Waymo</a>&nbsp;to help the company "continue to build the world's leading autonomous driving technology company."
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41324450/elon-musk-says-spacexs-next-generation-starlink-satellites-will-be-so-big-that-only-starship-can-lau" target="_blank" rel="noreferrer noopener">Elon Musk Says SpaceX&#8217;s Next-Generation Starlink Satellites Will Be ‘So Big That Only Starship Can Launch Them:&#8217; Will Offer 10X Increase In Bandwidth And Reduced Latency</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

GOOG

GOOGL

Waymo Offers Free Credits To Riders Traveling To Select Transit Stations In The Bay Area: Here's How Much You Can Get

Coca-Cola Europacific Partners plc (&quot;CCEP&quot; or the &quot;Company&quot;) today confirms notification of transfer of UK listing category from the Equity Shares (Transition) category to the Equity Shares (Commercial Companies) category of the Official List

Coca-Cola European Partners plc Ordinary Shares

CCEP

Coca-Cola Europacific Partners To Shifts To Commercial Companies Category, Paving The Way For FTSE Index Eligibility

NYCB

Reported Earlier, Flagstar Bank, Subsidiary of New York Community Bancorp, Cuts 8% of Workforce In Strategic Transformation And Cost-Cutting Initiative

Lotus continues to achieve top-rate growth among traditional luxury car brands, delivering 7,543 vehicles1&nbsp;in the first nine months of 2024, representing a year-on-year increase of&nbsp;134%. Global allocation in terms of deliveries remained well-distributed, with Europe, China, North America and the Rest of the World regions each contributing about&nbsp;20-35%&nbsp;of the total deliveries. In the&nbsp;third quarter&nbsp;of 2024, Emeya (GT, Sedan) was delivered to Europe, whilst Eletre (SUV) reached markets including the GCC, Japan and Korea.

Reported Earlier, Lotus Technology Reports 134% YoY Vehicle Delivery Surge In First Nine Months Of 2024

Econ #s

U.K. Retail Sales (YoY) For September 3.9% Vs. 3.2% Est.; 2.3% (Revised) Prior

U.K. Retail Sales (MoM) For September 0.3% Vs. -0.3% Est.; 1.0% Prior

U.K. Core Retail Sales (MoM) For September 0.3% Vs. -0.3% Est.; 1.1% Prior

U.K. Core Retail Sales (YoY) For September 4.0% Vs. 3.2% Est.; 2.2% (Revised) Prior

Netflix Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) Co-CEO&nbsp;Ted Sarandos on Thursday outlined why the streaming giant continues to hold an edge over YouTube, a subsidiary of Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google.
What Happened: During Netflix&#8217;s <a href="https://www.benzinga.com/news/earnings/24/10/41391637/netflix-q3-earnings-revenue-beats-eps-tops-q4-guidance-projects-subscriber-boost-from-squid-game-nf">third-quarter earnings</a> call, a question about&nbsp;YouTube&#8217;s growing share of TV&nbsp;consumption was raised.
In response, Sarandos highlighted Netflix&#8217;s commitment to investing in premium content to increase viewer engagement, stating, &#8220;Netflix is the best place&nbsp;for premium stories because we&#8217;re&nbsp;the home to the best&nbsp;storytellers.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/10/41375934/meta-confirms-layoffs-across-instagram-whatsapp-and-reality-labs-amid-strategic-reshuffle?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Meta Confirms Layoffs Across Instagram, WhatsApp And Reality Labs Amid Strategic Reshuffle</a>
Regarding YouTube, he said, &#8220;When I look at YouTube specifically, I&#8217;d say look, we compete directly with YouTube for people&#8217;s time, for the time they spend on that TV screen. But we have very different strengths.&#8221;
Another, Netflix Co-CEO Greg Peters added that Netflix plays a crucial role for consumers seeking high-quality movies and TV shows, and for creators looking for partners willing to share the inherent risks of bringing stories to life.
&#8220;A Hundred Years of Solitude, Senna, both coming from Latin America, which are huge, ambitious projects. It&#8217;s hard to imagine how those kind of big creative bets would be possible with YouTube&#8217;s model,&#8221; Peters stated.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Netflix&#8217;s third-quarter financial results showed a 15% year-over-year increase in revenue, beating Street consensus estimates.
Moreover, Netflix&#8217;s recent foray into live sports programming indicates a strategic shift from its traditional on-demand model. This move aims to capture high-impact moments and the <a href="https://www.benzinga.com/general/entertainment/24/10/41395213/netflixs-200b-hour-problem-why-live-sports-are-just-a-drop-in-the-streaming-ocean">excitement of global live events</a>, further enhancing viewer engagement.
During the <a href="https://www.benzinga.com/news/earnings/24/07/39849026/netflix-q2-earnings-highlights-revenue-beat-eps-beat-advertising-revenue-more-meaningful-squid-game" target="_blank" rel="noreferrer noopener">second-quarter earnings</a> call, Netflix executives were asked questions about YouTube.
At the time, Sarandos&nbsp;said, &#8220;So our two services — us and YouTube represent about 50% of all streaming to the TV in the U.S. and we use the U.S. only because that's where we have the data.&#8221;
&#8220;So really what we're focused on here is focusing ourselves on that other 80% of total TV time that isn't going to either us or YouTube,&#8221; he said in July.
Sarandos <a href="https://www.benzinga.com/general/entertainment/24/07/39853498/netflix-aims-to-capture-broader-tv-market-sees-youtube-as-both-competitor-and-partner-we-ki">reiterated Netflix&#8217;s commitment to focus</a> on the remaining 80% of the market during the third-quarter call too.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41356479/apple-spark-hope-for-americas-semiconductor-comeback-key-supplier-tsmc-reportedly-begins-producing-c?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Spark Hope For America&#8217;s Semiconductor Comeback: Key Supplier TSMC Reportedly Begins Producing Chips In US For iPhone Maker</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Unsplash

Entertainment

Equities

Netflix's Ted Sarandos Downplays Concerns Of YouTube's Growing Share Of TV Consumption: 'We're The Home To The Best Storytellers'

Orders and deliveries
In Q3, net order intake decreased by 8% to 43,234 trucks and deliveries decreased by 16% to 46,266 units. Deliveries of heavyduty trucks decreased by 9%, of medium-duty trucks by 21% and of light-duty trucks by 61%.

VLVLY

Volvo's Q3 Saw 8% Drop In Net Order Intake To 43,234 Trucks, With Deliveries Down 16% To 46,266 Units

Volvo (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VLVLY#OTC">VLVLY</a>) reported quarterly earnings of $0.47 per share. This is a 26.18 percent decrease over earnings of $0.64 per share from the same period last year. The company reported $11.22 billion in sales this quarter. This is a 8.38 percent decrease over sales of $12.25 billion the same period last year

VLVCY

Volvo Q3 EPS $0.47 Down From $0.64 YoY, Sales $11.22B Down From $12.25B YoY

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enliven Therapeutics (ELVN – Research Report), Harmo...

Analysts Are Bullish on These Healthcare Stocks: Enliven Therapeutics (ELVN), Harmony Biosciences Holdings (HRMY)

Harmony Biosciences Holdings ( ($HRMY) ) has provided an announcement. Harmony Biosciences Holdings, Inc. is set to engage investors and market ent...

Harmony Biosciences Unveils Future Strategies on Investor Day

Goldman Sachs analyst Corinne Johnson reiterated a Sell rating on Harmony Biosciences Holdings (HRMY – Research Report) today. The company's shares...

Harmony Biosciences Holdings (HRMY) Receives a Sell from Goldman Sachs

Needham analyst Ami Fadia maintained a Buy rating on Harmony Biosciences Holdings (HRMY – Research Report) today and set a price target of $52.00. ...

Optimistic Growth and Innovation Outlook for Harmony Biosciences Holdings: A Buy Rating Analysis

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Harmony Biosciences Holdings (HRMY – Research Report), wit...

Piper Sandler Keeps Their Buy Rating on Harmony Biosciences Holdings (HRMY)

In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on Harmony Biosciences Holdings (HRMY – Research Report), w...

Oppenheimer Sticks to Their Buy Rating for Harmony Biosciences Holdings (HRMY)

Avidity Biosciences: Good Prospects, But We Are A Little Late

The biotech industry is flourishing with increasing investments and breakthrough developments. Thus, fundamentally solid small-cap biotech stocks BioCryst Pharmaceuticals (BCRX), Harmony Biosciences (HRMY), and Entrada Therapeutics (TRDA) with potential upside could be worth buying. Read more... The biotech industry is experiencing strong growth and expansion amid increasing investments, robust demand, and a boosting IPO market. Also, the recently announced Fed rate cuts will benefit the market operations.
Amid this backdrop, investors could consider investing in solid small-cap biotech stocks BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>), Harmony Biosciences Holdings, Inc. (<a href="https://stocknews.com/stock/HRMY/">HRMY</a>), and Entrada Therapeutics, Inc. (<a href="https://stocknews.com/stock/TRDA/">TRDA</a>) for significant upside.
The biotech industry continued to rebound in 2024 with pent-up demand, improving technologies, and an optimistic IPO market. September was marked as the <a href="https://www.reuters.com/markets/deals/camp4-therapeutics-seeks-up-283-mln-valuation-us-ipo-2024-10-07/#:~:text=Oct%207%20(Reuters)%20%2D%20Three,after%20a%20two%2Dyear%20slump.">busiest month for healthcare IPOs</a>, encouraged by some strong debuts.
Also, innovative discoveries in areas like oncology, immunology, and neurology supported by increasing investments are bound to propel the biotech industry's prospects. According to <a href="https://investingnews.com/biotech-forecast/#toggle-gdpr">Biopharma Dive</a>, over 12 deals were reported during the second quarter, totaling 28 this year, reflecting strong biotech mergers and acquisitions (M&amp;A) activities.
Besides, <a href="https://www.biopharmadive.com/news/biotech-interest-rates-impact-startups-venture-capital/727479/">the Fed's decision to cut rates</a> for the first time in more than four years will ease the funding environment and also accelerate early-stage drugmakers' operations, and could potentially spur investments in biotech companies.
In addition, the growing R&amp;D initiatives and adoption of digital technologies worldwide would benefit the industry's growth. As per a report by Precedence Research, the <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20global%20biotechnology%20market%20size%20accounted%20for%20USD%201.55%20trillion,USD%20521.02%20billion%20in%202023.">global biotechnology market</a> is expected to reach $4.61 trillion by 2034, growing at a CAGR of 11.5%.
Amid this economic and industry background, small-cap biotech stocks offer great potential for high returns and long-term growth for investors. Small-cap stocks are low-cost and have more growth opportunities.
Therefore, let's delve into the fundamentals of the top three <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>)
BCRX is a biotechnology company that develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names, and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
On September 30, BCRX was awarded a $69 million contract by the U.S. Department of Health and Human Services for the procurement of up to 95,625 doses over a five-year period of RAPIVAB&#xAE; (peramivir injection) for treating influenza.
On July 9, BCRX received approval from the General Directorate of Medicines, Supplies, and Drugs (DIGEMID) in Peru for its oral, once-daily ORLADEYO&#xAE; (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.
During the second quarter that ended June 30, 2024, BCRX's total revenues grew 32.5% from the prior year's quarter to $109.33 million. The company's adjusted income from operations was $21.93 million for the quarter.
Furthermore, the company's cash, cash equivalents and, investments and total assets were $336.34 million and $472.42 million as of June 30, 2024.
Analysts expect BCRX's <a href="https://www.investopedia.com/terms/r/revenue.asp">revenue</a> for the third quarter (ended September 2024) to grow 31.3% year-over-year to $113.89 million. Its revenue for the fiscal year 2024 is expected to grow 30.9% year-over-year to $433.84 million. Also, the company topped the consensus revenue estimates in all of the four trailing quarters.
Shares of BCRX have surged 56.2% over the past six months and 17.1% over the past year to close the last trading session at $7.20. Moreover, Wall Street analysts expect the stock to reach $15.33 in the upcoming 12 months, indicating a <a href="https://www.tipranks.com/stocks/bcrx/forecast">potential upside of 116.07%</a>.
BCRX's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
BCRX has a B grade for Quality, Growth, and Value. It is ranked #21 out of 331 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
In addition to the POWR Ratings we've stated above, we also have BCRX ratings for Sentiment, Momentum, and Stability. Get all BCRX ratings <a href="https://stocknews.com/stock/BCRX/">here</a>.
Stock #2: Harmony Biosciences Holdings, Inc. (<a href="https://stocknews.com/stock/HRMY/">HRMY</a>)
HRMY is a commercial-stage pharmaceutical company that focuses on developing and commercializing therapies for patients with rare and other neurological diseases. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action to treat excessive daytime sleepiness in adult patients with narcolepsy.
On June 24, HRMY announced that the U.S. FDA approved its supplemental New Drug Application (sNDA) for WAKIX&#xAE; (pitolisant) tablets treating excessive daytime sleepiness (EDS) in pediatric patients six years of age and older with narcolepsy. With this, WAKIX became the first FDA-approved non-scheduled treatment for pediatric narcolepsy patients.
During the second quarter that ended June 30, 2024, HRMY's net product revenue increased 28.8% year-over-year to $172.81 million. Its gross profit increased 28.8% from the year-ago value to $140.67 million. The company's non-GAAP adjusted net income and EPS came in at $60.61 million and $1.05 per share, up 32.1% and 38.1% from the prior year's quarter, respectively.
Additionally, the company's total assets stood at $858.38 million as of June 30, 2024, compared to $811.45 million as of December 31, 2023.
Street expects HRMY's revenue for the third quarter (ended September 2024) to increase 15.3% year-over-year to $184.81 million, while its EPS is expected to grow 7.2% year-over-year to $0.68, respectively. Furthermore, the company surpassed the consensus revenue estimates in all of the trailing four quarters.
HRMY's stock has gained 16.5% over the past six months and 6.6% over the past year to close the last trading session at $34.75. Wall Street expects the stock to reach $52 in the near term, indicating a <a href="https://www.tipranks.com/stocks/hrmy/forecast">potential upside of 49.38%</a>.
HRMY's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
The stock has an A grade for Value and a B grade for Quality. HRMY is ranked #14 among 331 stocks in the Biotech industry.
<a href="https://stocknews.com/stock/HRMY/">Click here</a> to access HRMY's ratings for Momentum, Growth, Stability, and Sentiment.
Stock #1: Entrada Therapeutics, Inc. (<a href="https://stocknews.com/stock/TRDA/">TRDA</a>)
TRDA is a clinical-stage biotechnology company that develops endosomal escape vehicle therapeutics for treating multiple neuromuscular diseases. The company's EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs.
On June 24, TRDA announced positive preliminary data from its Phase 1 clinical trial, ENTR-601-44-101. It reported that ENTR-601-44 was taken well by healthy volunteers with no serious or drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams, or laboratory assessments.
ENTR-601-44 also showed significant plasma concentration, muscle concentration, and exon skipping at levels suggesting potential for a clinically meaningful starting dose in planned upcoming patient trials.
During the second quarter, which ended June 30, 2024, TRDA's collaboration revenue increased 421.1% year-over-year to $94.69 million, and its income from operations was $53.42 million for the same period. The company's net income amounted to $55.03 million or $1.55 per share, against a net loss of $25.93 million and $0.78 per share during the prior year's quarter, respectively.
Street expects TRDA's revenue for the fiscal year (ending December 2024) to increase 36.3% year-over-year to $175.89 million, and its EPS for the same period is expected to be $0.62. Also, the company has surpassed the consensus revenue estimates in each of the trailing four quarters, which is impressive.
TRDA's stock has gained 21.9% over the past six months and 15% over the past year to close the last trading session at $16.39. Also, Wall Street analysts expect the stock to reach $21.50 in the near term, indicating a potential <a href="https://www.tipranks.com/stocks/trda/forecast">upside of 32.55%</a>.
TRDA's POWR Ratings reflect its robust outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has an A grade for Value and Quality. It also has a B grade for Sentiment. Within the same industry, TRDA is ranked #13 among 331 stocks.
<a href="https://stocknews.com/stock/TRDA/">Click here</a> to access additional ratings of TRDA for Momentum, Growth, and Stability.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
HRMY shares were unchanged in after-hours trading Wednesday. Year-to-date, HRMY has gained 4.02%, versus a 22.57% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/hrmy-bcrx-trda-3-small-cap-biotech-stocks-to-buy-for-major-upside/>3 Small-Cap Biotech Stocks to Buy for Major Upside</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Small-Cap Biotech Stocks to Buy for Major Upside

IYH: Healthcare Dashboard For October

Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on HRMY stock, giving a Buy rating on October 10. Graig Suvannavejh...

Strategic Positioning and Growth Potential in Harmony Biosciences' Epilepsy Market Venture

ABBV

ALKS

AMGN

BCRX

CDMO

COLL

ELVN

EXEL

GEHC

HRMY

INVA

RSPH

TRDA

Press Releases

HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1

HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY

HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)

HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 6, 2024

venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies

Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028

HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

HARMONY BIOSCIENCES TO HOST FIRST INVESTOR DAY ON OCTOBER 1, 2024

HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY

Comments

Harmony Biosciences

Notizie

Ultime notizie per Harmony Biosciences (NASDAQ:HRMY) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO